Drugs / Acumapimod
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03498170 | Mar → May 2018 | — | Mereo BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT02926326 | Sep → Oct 2016 | — | Mereo BioPharma | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02700919 | Aug 2016 → Nov 2017 | chronic obstructive pulmonary disease | Mereo BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT01336959 | Sep 2011 → Nov 2013 | acute kidney injury | Mereo BioPharma | Terminated | No outcome recorded |
| Phase 2 | NCT01332097 | Mar 2011 → May 2013 | chronic obstructive pulmonary disease | Mereo BioPharma | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acumapimod | “Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).” PMID 31682162 ↗ Nov 2019 |
| Known as | BCT197 | “Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD.” PMID 31682162 ↗ Nov 2019 |
| Action | Inhibit | “Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).” PMID 31682162 ↗ Nov 20191“MAP kinase p38 alpha inhibitor” CHEMBL5314397 ↗ |
| Modality | Small molecule | — CHEMBL5314397 ↗ |
| Route | Oral | “Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).” PMID 31682162 ↗ Nov 2019 |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL5314397 ↗ |